Endurant Capital Management LP Tcr2 Therapeutics Inc. Transaction History

Endurant Capital Management LP

  • $0
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$13.1 - $20.69 $504,271 - $796,440
-38,494 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$6.51 - $16.85 $250,595 - $648,623
38,494 New
38,494 $591,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Endurant Capital Management LP Portfolio

Follow Endurant Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Endurant Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email